Novel HSP90 inhibitors that do not contain the benzoquinone component found in geldanamycin, which is believed to contribute to hepatotoxicity, may offer potential prospects for HSP90 inhibition in the therapy of HCC in the future (Pearl et al., 2008). Here, HSP90AB1 is linked to hepatocellular carcinoma.